Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Sleep-disordered breathing (SDB) is common and associated with worse cardiovascular and brain health. Hispanic/Latino individuals are at increased risk for SDB. OSA is the most studied SDB; it is characterized by apnea-hypopnea events and has been linked to adverse vascular health and cognitive sequelae. Less is known about upstream factors such as parameters of breathing. Breathing dynamics such as breathing rate and breathing rate variability have been linked to changes in mood and oscillatory brain activity. Their relationships with cognitive performance, particularly in diverse and understudied Hispanic/Latino communities, are unknown.
Research Question: What is the association between parameters of breathing and cognitive outcomes?
Study Design And Methods: The Hispanic Community Health Study/Study of Latinos (HCHS/SOL) is a prospective study of diverse Hispanic/Latino subjects. Individuals were given an ARES monitor for in-home sleep testing. Breathing information was extracted from the cannula channel, and parameters of breathing were calculated by using bycycle, a novel tool for time series analysis. A total of 6,737 individuals were included in the study.
Results: Faster breathing rate was linked with worse domain-specific and global cognitive performance (b = -0.011; < .01), and breathing rate variability was associated with worse global cognitive performance (β = -0.022; < .05). In interaction models, breathing rate variability was found to be significantly associated with worse verbal fluency and global cognitive performance in women but not in men.
Interpretation: Parameters of breathing are novel methods for understanding SDB and cognitive function. These results also suggest that faster breathing rate variability in women, but not in men, is related to worse cognitive function.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12074581 | PMC |
| http://dx.doi.org/10.1016/j.chpulm.2024.100102 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Initiation of tocilizumab within 24 hours in acute necrotizing encephalopathy is related to a good outcome: a systematic review.
J Neurol
September 2025
Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Objective: To evaluate the clinical efficacy of tocilizumab, a interleukin-6 (IL-6) receptor blocker, for the treatment of acute necrotizing encephalopathy (ANE).
Methods: PubMed, Cochrane Library, Embase, and Web of Science were searched for systematic review based on PRISMA guidelines. ANE patients treated with and without tocilizumab were included.
How to distinguish opioid toxicity from natural dying in patients with advanced illness and how to manage opioid toxicity.
Clin Med (Lond)
September 2025
Hull University Teaching Hospitals NHS Trust, Castle Rd, Cottingham HU16 5JQ, UK.
Patients with advanced, life limiting illness might develop pain or breathlessness, requiring opioids. Opioid neurotoxicities, like sedation and delirium, overlap with signs of natural dying. Understanding natural dying is a core clinical skill for all health care professionals.
View Article and Find Full Text PDFNon-communicable disease burden among middle-aged and older adults living with HIV in the Western Pacific region: A systematic review and meta-analysis.
Prev Med
September 2025
Department of Pharmacy, Taoyuan General Hospital, Ministry of Health and Welfare, No. 1492, Zhongshan Rd., Taoyuan 33004, Taiwan. Electronic address:
Objective: Middle-aged and older adults living with HIV in the Western Pacific Region (WPR) are experiencing accelerated aging and a rising burden of non-communicable disease (NCD)-related comorbidities. This systematic review and meta-analysis aimed to assess the burden of major NCDs-measured by prevalence, incidence, and mortality-among people living with HIV(PLWH) aged 40 years and older, in comparison to their HIV-negative counterparts.
Methods: A comprehensive literature search was conducted across Medline (1966-), Embase (1974-), Cochrane Library (1996-), Epistemonikos (established in 2012, with retrospective coverage), and Web of Science (1900-) to identify relevant studies published up to May 9, 2025.
Efficacy of dupilumab and mepolizumab in eosinophilic COPD: insights from phase 3 trials.
Respir Med
September 2025
Scottish Centre for Respiratory Research, School of Medicine, University of Dundee, Dundee, United Kingdom. Electronic address:
Background: Eosinophilic chronic obstructive pulmonary disease (eCOPD), characterized by type 2 inflammation, is an emerging target for biologic therapies.
Objective: To indirectly compare the efficacy of dupilumab and mepolizumab in eCOPD, defined as blood eosinophil counts ≥300 cells/μL, by synthesizing data from phase 3 randomized controlled trials: BOREAS and NOTUS for dupilumab, MATINEE for mepolizumab.
Methods: We performed an indirect comparison of trial primary and secondary outcomes including annual exacerbation rates (AER), quality of life (St.
Comparison of spontaneous breathing test techniques for heart failure patients: A single-center, prospective, open-label, randomized controlled study.
Heart Lung
September 2025
The First School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China; Department of Critical Care Medicine, General Hospital of Southern Theatre Command of Chinese PLA, Guangzhou 510010, China; Guangdong Branch Center, National Clinical Research Center for Geriatric Diseases,
Background: Standardized spontaneous breathing trial (SBT) techniques for patients with heart failure (HF) are lacking.
Objectives: To compare the efficacy of low-level pressure-supported ventilation (PSV) and T-piece SBT techniques in patients with HF.
Methods: This single-center, prospective, open-label, randomized controlled study enrolled mechanically ventilated adults with stage B HF (Nov 2022-Apr 2024).